Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Jul 11, 2005
Walter Reed NNZ-2566 Contract Expanded
Jun 06, 2005
FDA advances Neuren to Phase
May 30, 2005
Results of Annual General Meeting
May 30, 2005
AGM - CEO Presentation
May 20, 2005
Appendix 3B
Apr 29, 2005
Commitments Test Entity - First Quarter Report
Apr 22, 2005
Annual Report 2004 & Notice of AGM
Mar 31, 2005
Annual Report 2004
Mar 17, 2005
Neuren CEO Update March 2005
Mar 15, 2005
Walter Reed Collaboration
Previous
1
2
3
4
5
6
Next